Chenodeoxycholic acid is an endogenous bile acid synthesized by the liver; it acts as an agonist at the farnesoid X receptor (FXR). Chenodeoxycholic acid exhibits anticancer and gastrointestinal motility modulating activities. This compound treats chronic constipation and displays protective benefit against NSAID-induced gastrointestinal injury. Chenodeoxycholic acid also induces apoptosis, decreases PKC activity, and inhibits growth of ovarian cancer cells.
| Cas No. | 474-25-9 |
|---|---|
| Purity | ≥98% |
| Formula | C24H40O4 |
| Formula Wt. | 392.57 |
| Chemical Name | (3α,5β,7α)-3,7-Dihydroxycholan-24-oic acid |
| IUPAC Name | (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| Synonym | Chenodiol; CDC; Chenix; Chenossil; Fluibil; Hekbilin; Ulmenide |
| Melting Point | 119°C |
| Solubility | Soluble in methanol, acetone, or acetic acid. Practically insoluble in water, or benzene. |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | C2916 MSDS PDF |
|---|---|
| Info Sheet | C2916 Info Sheet PDF |
Fiorucci S, Mencarelli A, Cipriani S, et al. Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. Br J Pharmacol. 2011 Dec;164(8):1929-38. PMID: 21564085.
Horowitz NS, Hua J, Powell MA, et al. Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol. 2007 Nov;107(2):344-9. PMID: 17720233.
Bazzoli F, Malavolti M, Petronelli A, et al. Treatment of constipation with chenodeoxycholic acid. J Int Med Res. 1983;11(2):120-3. PMID: 6852359.
